Literature DB >> 23389662

Rat brain-uptake index for phenylethylamine and various monomethylated derivatives.

Aron D Mosnaim1, Owen H Callaghan, Thomas Hudzik, Marion E Wolf.   

Abstract

Phenylethylamine and its monomethylated derivatives p-methylphenylethylamine, α-methylphenylethylamine, phenylethylamine itself, N-methylphenylethylamine, o-methylphenylethylamine, and β-methylphenylethylamine, readily cross the blood-brain barrier showing a brain-uptake index (%) ± SD (water considered 100 %), of 108 ± 11, 98 ± 14, 83 ± 6, 78 ± 11, 62 ± 7 and 56 ± 6, respectively (injection of tritiated water and 100 μg standard amine, which was measured by gas-liquid chromatography). Similar brain-uptake index values (determined by double isotope counting) were obtained for phenylethylamine and α-methylphenylethylamine (amphetamine) after the injection of tritiated water and C(14)-labeled amine (either 3 μg or when added 100 μg standard compound), suggesting that they entered the brain via passive diffusion. Accordingly, both amines distributed rather evenly in the various rat brain areas examined: uptake index (%) ± SD (double isotope counting; non-, and diluted labeled amine) for phenylethylamine (89 ± 8 and 78 ± 7, 83 ± 9 and 86 ± 9, 96 ± 6 and 84 ± 7) and for α-methylphenylethylamine (88 ± 11 and 87 ± 9, 93 ± 14 and 87 ± 11, 97 ± 12 and 87 ± 9) for the cerebellum, frontal cortex, and striatum, respectively. These results will aid a greater understanding of the pharmacological and behavioral effects observed after the administration of phenylethylamine and methylphenylethylamine derivatives.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389662     DOI: 10.1007/s11064-013-0988-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  28 in total

Review 1.  Trace amine receptors as targets for novel therapeutics: legend, myth and fact.

Authors:  Theresa A Branchek; Thomas P Blackburn
Journal:  Curr Opin Pharmacol       Date:  2003-02       Impact factor: 5.547

Review 2.  Drug delivery to the central nervous system: a review.

Authors:  Ambikanandan Misra; S Ganesh; Aliasgar Shahiwala; Shrenik P Shah
Journal:  J Pharm Pharm Sci       Date:  2003 May-Aug       Impact factor: 2.327

Review 3.  Receptors of mammalian trace amines.

Authors:  Anita H Lewin
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

4.  Enzymatic isotopic assay for and presence of beta-phenylethylamine in brain.

Authors:  J M Saavedra
Journal:  J Neurochem       Date:  1974-02       Impact factor: 5.372

5.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.

Authors:  J R Bunzow; M S Sonders; S Arttamangkul; L M Harrison; G Zhang; D I Quigley; T Darland; K L Suchland; S Pasumamula; J L Kennedy; S B Olson; R E Magenis; S G Amara; D K Grandy
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

6.  Identification of trace-amine-associated receptors (TAAR) in the rat aorta and their role in vasoconstriction by β-phenylethylamine.

Authors:  Martina Fehler; Kenneth J Broadley; William R Ford; Emma J Kidd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-09-01       Impact factor: 3.000

7.  Determination of regional distributions of phenylethylamine and meta- and para-tyramine in rat brain regions and presence in human and dog plasma by an ultra-sensitive negative chemical ion gas chromatography-mass spectrometric (NCI-GC-MS) method.

Authors:  D A Durden; B A Davis
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

Review 8.  The potential of trace amines and their receptors for treating neurological and psychiatric diseases.

Authors:  M D Berry
Journal:  Rev Recent Clin Trials       Date:  2007-01

9.  Direct effect of phenylethylamine upon isolated rat aortic strip.

Authors:  T R Hansen; J Greenberg; A D Mosnaim
Journal:  Eur J Pharmacol       Date:  1980-05-02       Impact factor: 4.432

10.  Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethylamines in insulin-dependent diabetic subjects.

Authors:  A D Mosnaim; F Karoum; A Zeller; O H Callaghan; S P Singh; M E Wolf
Journal:  Clin Chim Acta       Date:  1982-12-23       Impact factor: 3.786

View more
  7 in total

Review 1.  Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders.

Authors:  Ruyan Wu; Jun-Xu Li
Journal:  CNS Drugs       Date:  2021-11-12       Impact factor: 5.749

2.  Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection.

Authors:  Feihe Ma; Liu Yang; Zhuorui Sun; Jinjin Chen; Xuehui Rui; Zachary Glass; Qiaobing Xu
Journal:  Sci Adv       Date:  2020-07-24       Impact factor: 14.136

3.  Analgesic effects of β-phenylethylamine and various methylated derivatives in mice.

Authors:  Aron D Mosnaim; Thomas Hudzik; Marion E Wolf
Journal:  Neurochem Res       Date:  2014-06-26       Impact factor: 3.996

4.  Pharmacological characterization of a high-affinity p-tyramine transporter in rat brain synaptosomes.

Authors:  Mark D Berry; Shannon Hart; Anthony R Pryor; Samantha Hunter; Danielle Gardiner
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

5.  Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus.

Authors:  Youhei Obata; Mie Kubota-Sakashita; Takaoki Kasahara; Masafumi Mizuno; Takahiro Nemoto; Tadafumi Kato
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 6.  Potential Psychoactive Effects of Microalgal Bioactive Compounds for the Case of Sleep and Mood Regulation: Opportunities and Challenges.

Authors:  Bozena McCarthy; Graham O'Neill; Nissreen Abu-Ghannam
Journal:  Mar Drugs       Date:  2022-07-29       Impact factor: 6.085

Review 7.  Gut Bacteria and Neuropsychiatric Disorders.

Authors:  Leon M T Dicks; Diron Hurn; Demi Hermanus
Journal:  Microorganisms       Date:  2021-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.